Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0NTFBR
ADC Name
MEDI3726
Synonyms
MEDI3726; ADCT-401
   Click to Show/Hide
Organization
ADC Therapeutics (Originator);MedImmune (Top20 MNC)
Drug Status
Phase 1 (discontinued)
Drug-to-Antibody Ratio
2
Structure
Antibody Name
J591
  Antibody Info 
Antigen Name
Glutamate carboxypeptidase 2 (FOLH1)
  Antigen Info 
Payload Name
SG3199 (SC-DR002)
  Payload Info 
Therapeutic Target
Human deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mal-PEG8-Val-Ala-PABC
  Linker Info 
Conjugate Type
Reactive Cysteines
Combination Type
tesirine
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
Indication Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 New Drug Application Approved
Prostate cancer
1 Trials
Trial ID
NCT02991911
ADC-specific functional property(2027 Update)
Binding Affinity
Click To Hide/Show 2 ADC-specific functional property Data
Dissocation Constant (Kd) Binding Target Description Reference
1.67±0.83 nM
sPSMA
Affinity of MEDI3726 with Human sPSMA
[2]
3.11±0.19 nM
sPSMA
Affinity of MEDI3726 with Cynomolgus monkey sPSMA
[2]
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
Click To Hide/Show 24 Absorption Data Related to This Level
Standard Type Value Units Description Reference
Time to Maximum Concentration (Tmax) 0.12 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg.
 [1]
Maximum Observed Concentration (Cmax) 361.3 ng/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 172.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 183.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg, AUCinf.
 [1]
Time to Maximum Concentration (Tmax) 0.06 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg.
 [1]
Maximum Observed Concentration (Cmax) 1160 ng/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 1620 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1870 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg, AUCinf.
 [1]
Time to Maximum Concentration (Tmax) 0.11 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg.
 [1]
Maximum Observed Concentration (Cmax) 2915 ng/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 4362.5 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 4860 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg, AUCinf.
 [1]
Time to Maximum Concentration (Tmax) 0.12 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg.
 [1]
Maximum Observed Concentration (Cmax) 5164 ng/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 12452 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 13690 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg, AUCinf.
 [1]
Time to Maximum Concentration (Tmax) 0.07 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg.
 [1]
Maximum Observed Concentration (Cmax) 6590 ng/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 16320 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 18914.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg, AUCinf.
 [1]
Time to Maximum Concentration (Tmax) 0.11±0.04 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg.
 [1]
Maximum Observed Concentration (Cmax) 5770 ng/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 17160 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 20280 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg, AUCinf.
 [1]
Distribution
Click To Hide/Show 12 Distribution Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 172.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 183.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 1620 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1870 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 4362.5 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 4860 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 12452 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 13690 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 16320 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 18914.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 17160 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 20280 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg, AUCinf.
 [1]
Metabolism
Click To Hide/Show 12 Metabolism Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 172.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 183.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 1620 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1870 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 4362.5 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 4860 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 12452 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 13690 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 16320 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 18914.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 17160 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 20280 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg, AUCinf.
 [1]
Excretion
Click To Hide/Show 24 Excretion Data Related to This Level
Standard Type Value Units Description Reference
Elimination Half-Life (t1/2) 0.45 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 172.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 183.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg, AUCinf.
 [1]
Clearance (CL) 12933.3 mL/day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.03 mg/kg.
 [1]
Elimination Half-Life (t1/2) 5.41 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 1620 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1870 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg, AUCinf.
 [1]
Clearance (CL) 1743.3 mL/day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.06 mg/kg.
 [1]
Elimination Half-Life (t1/2) 3.39 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 4362.5 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 4860 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg, AUCinf.
 [1]
Clearance (CL) 3137.5 mL/day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.15 mg/kg.
 [1]
Elimination Half-Life (t1/2) 3.48 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 12452 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 13690 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg, AUCinf.
 [1]
Clearance (CL) 1420.8 mL/day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.20 mg/kg.
 [1]
Elimination Half-Life (t1/2) 4 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 16320 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 18914.3 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg, AUCinf.
 [1]
Clearance (CL) 1383.6 mL/day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.25 mg/kg.
 [1]
Elimination Half-Life (t1/2) 4.26 day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 17160 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 20280 ng*day/mL
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg, AUCinf.
 [1]
Clearance (CL) 1428.4 mL/day
Summary of mean (%CV) PK parameters of ADC after a single IV infusion of MEDI3726, 0.30 mg/kg.
 [1]
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Progression Free Survival  NCT02991911
PHASE1
A Phase 1/1b Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects With Metastatic Castration Resistant Prostate Cancer Who Have Received Prior Treatment With Abiraterone or Enzalutamide.

   Click to Show/Hide
Overall suvival (OS)  NCT02991911
PHASE1
A Phase 1/1b Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects With Metastatic Castration Resistant Prostate Cancer Who Have Received Prior Treatment With Abiraterone or Enzalutamide.

   Click to Show/Hide
Composite Response Rate (RR)  NCT02991911
Phase 1
A phase 1/1b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in subjects with metastatic castration resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.

   Click to Show/Hide
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 7 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 15.86
%
PC-3 cells
Prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 36.17
%
LNCaP cells
Prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 45.68
%
PC-3 cells
Prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 68.2
%
LNCaP cells
Prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 76.95
%
LNCaP cells
Prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 93.55
%
22RV1 cells
Prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 98.71
%
22RV1 cells
Prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Progression Free Survival
3.9 months
Patients Enrolled
Eligible participants must be ≥18 years with metastatic castration-resistant prostate cancer (mCRPC) progressing after abiraterone/enzalutamide therapy. Key exclusions include prior PSMA-directed therapies, recent anti-cancer treatments (within 21 days), brain metastases requiring treatment, radiation affecting >25% marrow-bearing bone, or history of significant peripheral vasculopathies.

   Click to Show/Hide
Administration Dosage
As of Sept 27 2019, 33 pts received MEDI3726. Median age was 71.0 yr. Median number of prior regimens was 4. Median follow-up was 5.4 mo. Drug-related AEs occurred in 30 (90.9%), being grade 3/4 in 15 (45.5%), serious in 11 (33.3%) and causing discontinuation in 13 (39.4%). There were no drug-related deaths. One pt at 0.3 mg/kg had a DLT of Grade 3 thrombocytopenia. No MTD was identified per mTPI; the MAD was 0.3 mg/kg.

   Click to Show/Hide
Related Clinical Trial
NCT Number NCT02991911  Clinical Status PHASE1
Clinical Description A Phase 1/1b Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects With Metastatic Castration Resistant Prostate Cancer Who Have Received Prior Treatment With Abiraterone or Enzalutamide.
Primary Endpoint
The study evaluates safety through monitoring adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) from informed consent through 90 days post-treatment, with laboratory parameters, vital signs, and ECG changes assessed up to 21-90 days after last MEDI3726 dose.
Other Endpoint
Efficacy is measured via RECIST v1.1 response, PSA50 reduction, and circulating tumor cell (CTC) conversion over 12-90 days. Pharmacokinetic analysis includes MEDI3726 plasma concentration, Cmax, AUC, clearance, and half-life, alongside immunogenicity assessment through anti-drug antibodies (ADAs) during the 90-day follow-up period.
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Overall suvival (OS)
10.6 months
Patients Enrolled
Eligible participants must be ≥18 years with metastatic castration-resistant prostate cancer (mCRPC) progressing after abiraterone/enzalutamide therapy. Key exclusions include prior PSMA-directed therapies, recent anti-cancer treatments (within 21 days), brain metastases requiring treatment, radiation affecting >25% marrow-bearing bone, or history of significant peripheral vasculopathies.

   Click to Show/Hide
Administration Dosage
As of Sept 27 2019, 33 pts received MEDI3726. Median age was 71.0 yr. Median number of prior regimens was 4. Median follow-up was 5.4 mo. Drug-related AEs occurred in 30 (90.9%), being grade 3/4 in 15 (45.5%), serious in 11 (33.3%) and causing discontinuation in 13 (39.4%). There were no drug-related deaths. One pt at 0.3 mg/kg had a DLT of Grade 3 thrombocytopenia. No MTD was identified per mTPI; the MAD was 0.3 mg/kg.

   Click to Show/Hide
Related Clinical Trial
NCT Number NCT02991911  Clinical Status PHASE1
Clinical Description A Phase 1/1b Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects With Metastatic Castration Resistant Prostate Cancer Who Have Received Prior Treatment With Abiraterone or Enzalutamide.
Primary Endpoint
The study evaluates safety through monitoring adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) from informed consent through 90 days post-treatment, with laboratory parameters, vital signs, and ECG changes assessed up to 21-90 days after last MEDI3726 dose.
Other Endpoint
Efficacy is measured via RECIST v1.1 response, PSA50 reduction, and circulating tumor cell (CTC) conversion over 12-90 days. Pharmacokinetic analysis includes MEDI3726 plasma concentration, Cmax, AUC, clearance, and half-life, alongside immunogenicity assessment through anti-drug antibodies (ADAs) during the 90-day follow-up period.
Experiment 3 Reporting the Activity Date of This ADC [4]
Efficacy Data Composite Response Rate (RR)
12.10%
Patients Enrolled
Patients with metastatic castration-resistant prostate cancer after disease progression on abiraterone and/or enzalutamide and taxane-based chemotherapy.
Administration Dosage
Administered at 0.015-0.30 mg/kg intravenously every 3 weeks until disease progression/unacceptable toxicity; The MTD was not identified; the MAD was 0.30 mg/kg.
Related Clinical Trial
NCT Number NCT02991911  Clinical Status Phase 1
Clinical Description A phase 1/1b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in subjects with metastatic castration resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 7 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 15.86% High PSMA expression (PSMA+++; 250,494 PSMA molecules/cell)
Method Description
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.33 mg/kg MEDI3726.
In Vivo Model PC-3 CDX model
In Vitro Model Prostate carcinoma PC-3 cells CVCL_0035
Experiment 2 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 36.17% Moderate PSMA expression (PSMA++; 43,766 PSMA molecules/cell)
Method Description
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.11 mg/kg MEDI3726.
In Vivo Model PC-3 CDX model
In Vitro Model Prostate carcinoma LNCaP cells CVCL_0395
Experiment 3 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 45.68% High PSMA expression (PSMA+++; 250,494 PSMA molecules/cell)
Method Description
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 1 mg/kg MEDI3726.
In Vivo Model PC-3 CDX model
In Vitro Model Prostate carcinoma PC-3 cells CVCL_0035
Experiment 4 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 68.20% Moderate PSMA expression (PSMA++; 43,766 PSMA molecules/cell)
Method Description
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.33 mg/kg MEDI3726.
In Vivo Model PC-3 CDX model
In Vitro Model Prostate carcinoma LNCaP cells CVCL_0395
Experiment 5 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 76.95% High PSMA expression (PSMA+++; 250,494 PSMA molecules/cell)
Method Description
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 1 mg/kg MEDI3726.
In Vivo Model PC-3 CDX model
In Vitro Model Prostate carcinoma LNCaP cells CVCL_0395
Experiment 6 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 93.55% Negative PSMA expression (PSMA-)
Method Description
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.33 mg/kg MEDI3726.
In Vivo Model PC-3 CDX model
In Vitro Model Prostate carcinoma 22RV1 cells CVCL_1045
Experiment 7 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.71% Negative PSMA expression (PSMA-)
Method Description
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 1 mg/kg MEDI3726.
In Vivo Model PC-3 CDX model
In Vitro Model Prostate carcinoma 22RV1 cells CVCL_1045
References
Ref 1 Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
Ref 2 Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
Ref 3 A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
Ref 4 Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clin Cancer Res. 2021 Jul 1;27(13):3602-3609.
Ref 5 CMB-401